BioSpaceOriginal article
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Data ReadoutnegativeNegative
AI Analysis
Summary
Agios Pharmaceuticals discontinued development of its next-generation sickle cell disease candidate after it failed to outperform both Novo Nordisk's PK activator and Agios' own asset currently under FDA review for the indication.
Outcome Details
Agios' next-generation sickle cell disease candidate failed to demonstrate superiority over Novo Nordisk's investigational PK activator and Agios' own asset under FDA review
Importance:6/10
Sentiment:
-0.90
sickle cell diseaseclinical trial failurecompetitive landscapedrug development
Read the original article
Published by BioSpace on July 21, 2026 2:42 PM